Psychiatry

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

Addiction treatment evolves by integrating biological health with psychological care, emphasizing a holistic approach for lasting recovery.

Physicians experience significant challenges with increasing administrative burdens impacting patient care. Study shows AI scribes can help reduce burnout.

A study finds older adults with depression and comorbid anxiety show less improvement after accelerated theta burst stimulation.

Findings suggest having GERD incurs an 18% greater risk of a new AUD diagnosis, presenting an opportunity to discuss alcohol use with patients.

Right transcutaneous auricular VNS (taVNS) acutely increases food liking in patients with MDD, especially those with high anhedonia, a study found.

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

An audio recap of the top 5 stories in healthcare news from the week of 10/12-18.

Study finds repetitive transcranial magnetic stimulation brings clinically meaningful improvements in quality of life for adults with MDD through 12 weeks.

Stay updated with the latest healthcare breakthroughs, including FDA updates and phase 3 trial readouts, in this week's essential news roundup.

Post-hoc analysis of a phase 3 trial reveals significant improvements in patients with MDD experiencing tachyphylaxis.

A study found magnetic seizure therapy matched ECT’s antidepressant efficacy while offering better cognitive preservation and fewer adverse events.

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.

Mellinger joins Liver Lineup to discuss current shortcomings in ALD diagnosis and care, the importance of addressing underlying alcohol use disorder, and more.

Study finds heart rate deceleration within 45 seconds of iTBS may serve as a biomarker for improved depression outcomes, regardless of stimulation site.

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.

Therapist Diana Guzman, LMHC, writes about attempting suicide despite counseling patients battling with suicidal ideation.

Explore the latest advancements in psychiatry, including FDA updates, emerging therapies, and promising clinical trial results for mental health treatments.

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

Both ACOG and AAP have released statements disagreeing with the FDA label change for acetaminophen to reflect autism risk in children if used during pregnancy.

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.